Capricor Therapeutics (NASDAQ:CAPR) Earns “Neutral” Rating from Alliance Global Partners

28 Jul 2026, 12:06 by Michael Walen · The Markets Daily

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “neutral” rating reissued by investment analysts at Alliance Global Partners in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. They currently have a $7.00 price target on the biotechnology company’s stock. Alliance Global Partners’ target price would suggest a potential upside of 0.14% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of Capricor Therapeutics in a research note on Monday. Roth Capital lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective for the company. in a research note on Monday. Oppenheimer reiterated an “outperform” rating on shares of Capricor Therapeutics in a report on Monday. B. Riley Financial reissued a “neutral” rating and set a $10.00 target price on shares of Capricor Therapeutics in a research report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Capricor Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $40.60.

Check Out Our Latest Analysis on CAPR

Capricor Therapeutics Stock Down 64.5%

Capricor Therapeutics stock opened at $6.99 on Tuesday. The firm’s fifty day moving average is $24.87 and its 200 day moving average is $27.34. Capricor Therapeutics has a 52-week low of $4.30 and a 52-week high of $40.37. The company has a market cap of $404.79 million, a price-to-earnings ratio of -3.01 and a beta of 0.42.

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, equities research analysts anticipate that Capricor Therapeutics will post -0.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the sale, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at $260,669.10. This represents a 75.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 50,000 shares of company stock worth $1,551,658. Corporate insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Suvretta Capital Management LLC bought a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $51,533,000. Tang Capital Management LLC purchased a new position in Capricor Therapeutics during the 4th quarter valued at $49,062,000. RA Capital Management L.P. purchased a new position in Capricor Therapeutics during the 4th quarter valued at $43,516,000. Darwin Global Management Ltd. bought a new position in Capricor Therapeutics in the 4th quarter valued at $23,168,000. Finally, SB Capital Management Inc purchased a new stake in Capricor Therapeutics in the fourth quarter worth $11,544,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Key Stories Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

Positive Sentiment: Capricor said its confidence in deramiocel remains unchanged and argued that the FDA materials provide an opportunity to clarify the therapy’s clinical data ahead of the advisory committee meeting. Capricor Comments on Briefing Materials
Neutral Sentiment: An FDA Cellular, Tissue, and Gene Therapies Advisory Committee is scheduled to review deramiocel’s efficacy and risk-benefit profile on July 29. The FDA’s target action date for the therapy’s application is August 22, making the meeting a key near-term catalyst. FDA staff flags concerns for Capricor’s Duchenne therapy
Neutral Sentiment: B. Riley reaffirmed a neutral rating with a $10 price target, while Roth Capital downgraded Capricor from buy to neutral and set a $7 target. The divergent targets reflect continued uncertainty surrounding the regulatory decision.
Negative Sentiment: FDA reviewers questioned whether deramiocel generated sufficient evidence of effectiveness and disputed Capricor’s characterization of its Phase 3 results. The concerns center on the strength and interpretation of the clinical data, creating a material risk that approval could be delayed or denied. FDA questions efficacy of Capricor’s Duchenne drug
Negative Sentiment: The FDA’s criticism triggered a major reassessment of Capricor’s valuation because deramiocel is the company’s leading clinical and commercial opportunity. The stock is now trading near its 52-week low and well below its 50-day and 200-day moving averages. Capricor Therapeutics Shares Slide on Negative FDA Comments
Negative Sentiment: Several law firms announced investigations into potential securities-law violations, alleging that Capricor may have made misleading statements or failed to disclose material information about deramiocel’s clinical results. These announcements add legal and reputational overhang, although they do not establish wrongdoing. Securities Fraud Investigation Into Capricor Therapeutics

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.